Outset Medical Reports Second Quarter 2024 Financial Results

Rhea-AI Summary

Outset Medical (Nasdaq: OM) reported Q2 2024 financial results, showing mixed performance. Revenue decreased to $27.4 million from $36.0 million in Q2 2023, primarily due to a decline in product revenue. However, recurring revenue from Tablo cartridges and service increased by 24%. The company saw significant improvement in gross margins, with total gross margin rising to 35.7% from 21.4% year-over-year. Operating expenses decreased by 21% to $40.5 million. Net loss narrowed to $34.5 million, or $(0.66) per share. Outset revised its 2024 revenue guidance downward to approximately $110 million, citing lower-than-expected new console placements.

Positive

• Recurring revenue from Tablo cartridges and service increased by 24% year-over-year
• Total gross margin improved significantly to 35.7% from 21.4% in Q2 2023
• Operating expenses decreased by 21% to $40.5 million
• Net loss narrowed to $34.5 million from $44.0 million in Q2 2023

Negative

• Revenue decreased to $27.4 million from $36.0 million in Q2 2023
• Product revenue declined to $19.2 million
• New console placements were below expectations
• Full-year 2024 revenue guidance revised downward to $110 million from previous $145-$153 million range

Financial Analyst

Outset Medical's Q2 2024 results reveal a concerning trend. Revenue declined to $27.4 million from $36.0 million year-over-year, primarily due to a drop in product revenue. However, there are some positive aspects to consider:

• Recurring revenue from Tablo cartridges and service increased by 24%
• Gross margin improved significantly to 35.7% from 21.4%
• Operating expenses decreased by 21%

The company's revised 2024 revenue guidance of approximately $110 million, down from $145-153 million, is a red flag for investors. This substantial reduction suggests challenges in market penetration and sales execution. The improved gross margins and reduced operating expenses indicate efforts to enhance profitability, but may not be enough to offset the revenue decline.

Medical Technology Expert

The Tablo dialysis system's high utilization rates and record treatment levels demonstrate its strong value proposition in the dialysis market. However, the decline in new console placements is concerning and suggests potential market saturation or competitive pressures. The 24% increase in recurring revenue from cartridges and services is a positive indicator of customer retention and usage. The company's focus on improving execution to drive long-term growth is crucial, but the effectiveness of these measures remains to be seen. The dialysis market's evolving landscape, including shifts towards home-based treatments, may present both opportunities and challenges for Outset Medical's technology adoption.

Market Research Analyst

Outset Medical's Q2 results highlight a disconnect between product adoption and utilization. While existing Tablo systems are seeing high usage, new placements are lagging. This could indicate:

• Market saturation in current segments
• Pricing or reimbursement challenges
• Competitive pressures from traditional dialysis providers

The significant downward revision in revenue guidance suggests systemic issues rather than temporary setbacks. Investors should closely monitor the company's strategies to address these challenges, particularly in expanding its market reach and improving sales execution. The improved gross margins and reduced operating expenses demonstrate effective cost management, but sustainable growth will ultimately depend on rekindling product revenue.

SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2024.

“During the quarter, the number of treatments performed each month on Tablo continued at record levels, as utilization remained high and gross margin materially expanded as it has each quarter for more than 3 years,” said Leslie Trigg, Chair and Chief Executive Officer. “These results reflect the strength and differentiation of Tablo and the positive impact it is having on the lives of patients and providers.

“At the same time, new console placements were below our expectations and will be lower than we originally forecasted for the year. We are taking clear steps to improve our execution and grow the business over the long term to bring the benefits of Tablo to even more providers and dialysis patients.”

Second Quarter 2024 Financial Results

Revenue for the second quarter was $27.4 million compared to $36.0 million in the second quarter of 2023, driven by a decline in product revenue to $19.2 million. Service and other revenue was $8.2 million, an increase of 21.5% compared to $6.7 million in the second quarter of 2023. Recurring revenue from the sale of Tablo cartridges and service increased by 24% as compared to the prior-year period.

Total gross profit was $9.8 million, compared to $7.7 million for the second quarter of 2023. Total gross margin was 35.7%, compared to 21.4% in the second quarter of 2023. On a non-GAAP basis, gross margin improved to 37.3% from 22.5% in the second quarter of 2023. Product gross profit was $8.7 million, compared to $7.1 million in the second quarter of 2023. Product gross margin was 45.1%, compared to 24.3% in the second quarter of 2023. Service and other gross profit was $1.1 million, compared to $0.6 million in the second quarter of 2023. Service and other gross margin was 13.6%, compared to 8.7% in the second quarter of 2023.

Operating expenses declined 21% from the prior-year period to $40.5 million, including research and development (R&D) expenses of $9.7 million, sales and marketing (S&M) expenses of $18.1 million, and general and administrative (G&A) expenses of $12.7 million. This compared to operating expenses of $51.2 million in the second quarter of 2023, including R&D expenses of $14.9 million, S&M expenses of $25.0 million, and G&A expenses of $11.3 million.

Excluding stock-based compensation expense and severance and related charges, net of adjustments to compensation accrual, non-GAAP operating expenses were $31.2 million, including R&D expenses of $7.5 million, S&M expenses of $15.5 million, and G&A expenses of $8.2 million.

Net loss was $34.5 million, or $(0.66) per share, compared to net loss of $44.0 million, or $(0.90) per share, for the same period in 2023. On a non-GAAP basis, net loss was $24.7 million, or $(0.47) per share, compared to non-GAAP net loss of $33.9 million, or $(0.69) per share for the same period in 2023.

Total cash, including restricted cash, cash equivalents and short-term investments, was $198.2 million as of June 30, 2024.

Full Year 2024 Financial Guidance

Outset now expects 2024 revenue to be approximately $110 million, revised from a prior range of $145 million to $153 million, and non-GAAP gross margin to be in the low-to-mid 30% range, revised from prior guidance in the low-30% range for 2024 and exiting the year in the mid-30% range for the fourth quarter.

Webcast and Conference Call Details

Outset will host a conference call today, August 7, 2024, at 2:00 p.m. PT / 5:00 p.m. ET to discuss its second quarter 2024 financial results. Those interested in listening to the conference call may do so by registering online. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.outsetmedical.com. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures

The Company may report non-GAAP results for gross profit/loss, gross margin, operating expenses, operating margins, net income/loss, basic and diluted net income/loss per share, other income/loss, and cash flows. These non-GAAP financial measures are in addition to, and not a substitute for, or superior to, financial measures calculated in accordance with GAAP. As listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release, the Company’s GAAP financial measures include stock-based compensation expense, as well as severance and related charges net of the reversal of compensation accruals for impacted employees. Stock-based compensation is a non-cash expense, and severance and related charges arise outside the ordinary course of continuing operations and are not reflective of the Company's current operating performance. As such, management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance and period-to-period comparisons. There are limitations related to the use of non-GAAP financial measures because they are not prepared in accordance with GAAP, may exclude significant expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the Appendix A of this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the Company’s possible or assumed future results of operations and financial position, including expectations regarding projected revenues, gross margin, operating expenses, capital expenditures, cash burn, cash position, profitability and outlook; statements regarding the anticipated impacts and benefits of the Company’s cost reduction actions, initiatives to optimize the commercial organization and restructurings; statements regarding the Company’s overall business strategy, plans and objectives of management; the Company’s expectations regarding the market sizes and growth potential for Tablo and the total addressable market opportunities for Tablo; continued execution of the Company’s initiatives designed to expand gross margins; the Company’s ability to respond to and resolve any reports, observations or other actions by the Food and Drug Administration or other regulators in a timely and effective manner; as well as the Company’s expectations regarding the impact of macroeconomic factors on the Company, its customers and suppliers. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

Outset Medical, Inc. Condensed Statements of Operations (in thousands, except per share amounts) (unaudited)
		Three Months Ended										Six Months Ended
		June 30,										June 30,
		2024					2023					2024					2023
Revenue:
Product revenue		$	19,238				$	29,330				$	39,666				$	57,109
Service and other revenue			8,150					6,710					15,890					12,398
Total revenue			27,388					36,040					55,556					69,507
Cost of revenue:
Cost of product revenue (2)			10,567					22,212					23,148					43,029
Cost of service and other revenue			7,039					6,125					14,411					12,347
Total cost of revenue			17,606					28,337					37,559					55,376
Gross profit (1)			9,782					7,703					17,997					14,131
Gross margin (1)			35.7		%			21.4		%			32.4		%			20.3		%
Operating expenses:
Research and development (2)			9,734					14,906					22,369					28,699
Sales and marketing (2)			18,128					24,985					39,176					49,318
General and administrative (2)			12,684					11,290					24,128					23,077
Total operating expenses			40,546					51,181					85,673					101,094
Loss from operations			(30,764	)				(43,478	)				(67,676	)				(86,963	)
Interest income and other income, net			2,471					2,668					5,569					5,316
Interest expense			(6,010	)				(3,103	)				(11,978	)				(6,045	)
Loss before provision for income taxes			(34,303	)				(43,913	)				(74,085	)				(89,059	)
Provision for income taxes			151					133					313					325
Net loss		$	(34,454	)			$	(44,046	)			$	(74,398	)			$	(89,384	)
Net loss per share, basic and diluted		$	(0.66	)			$	(0.90	)			$	(1.45	)			$	(1.79	)
Shares used in computing net loss per share, basic and diluted			51,880					48,951					51,391					49,085

(1) Gross profit and gross margin by source consisted of the following:
		Three Months Ended										Six Months Ended
		June 30,										June 30,
		2024					2023					2024					2023
Gross profit
Product revenue		$	8,671				$	7,118				$	16,518				$	14,080
Service and other revenue			1,111					585					1,479					51
Total gross profit		$	9,782				$	7,703				$	17,997				$	14,131
Gross margin
Product revenue			45.1		%			24.3		%			41.6		%			24.7		%
Service and other revenue			13.6		%			8.7		%			9.3		%			0.4		%
Total gross margin			35.7		%			21.4		%			32.4		%			20.3		%
(2) Include stock-based compensation expense and severance and related charges, net as follows:
		Three Months Ended										Six Months Ended
Stock-based compensation expense		June 30,										June 30,
		2024					2023					2024					2023
Cost of revenue		$	531				$	403				$	796				$	761
Research and development			2,293					2,824					4,625					5,439
Sales and marketing			2,494					3,545					3,953					6,143
General and administrative			4,502					3,333					8,649					6,300
Total stock-based compensation expense		$	9,820				$	10,105				$	18,023				$	18,643
		Three Months Ended										Six Months Ended
Severance and related charges, net*		June 30,										June 30,
		2024†					2023					2024					2023
Cost of revenue		$	(78	)			$	—				$	201				$	—
Research and development			(29	)				—					963					—
Sales and marketing			99					—					892					—
General and administrative			(41	)				—					370					—
Total severance and related charges, net		$	(49	)			$	—				$	2,426				$	—
* Net of adjustments to compensation accrual
† These amounts represent the change in estimated accrual from March 31, 2024

Outset Medical, Inc. Condensed Balance Sheets (in thousands, except per share amounts)
		June 30,				December 31,
		2024				2023
		(Unaudited)
Assets
Current assets:
Cash and cash equivalents		$	37,859			$	68,509
Short-term investments			156,989				134,815
Accounts receivable, net			34,121				32,980
Inventories			61,599				49,215
Prepaid expenses and other current assets			4,569				5,700
Total current assets			295,137				291,219
Restricted cash			3,329				3,329
Property and equipment, net			10,873				13,273
Operating lease right-of-use assets			4,675				5,375
Other assets			520				605
Total assets		$	314,534			$	313,801
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	5,255			$	5,827
Accrued compensation and related benefits			11,431				19,005
Accrued expenses and other current liabilities			9,747				13,459
Accrued warranty liability			2,199				3,712
Deferred revenue, current			13,108				11,727
Operating lease liabilities, current			1,693				1,593
Total current liabilities			43,433				55,323
Accrued interest			1,762				896
Deferred revenue			130				101
Operating lease liabilities			3,616				4,482
Term loans			196,994				130,113
Total liabilities			245,935				190,915
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of June 30, 2024 and December 31, 2023			—				—
Common stock, $0.001 par value; 300,000 shares authorized as of June 30, 2024 and December 31, 2023; 52,084 and 50,317 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively			52				50
Additional paid-in capital			1,104,994				1,084,515
Accumulated other comprehensive income (loss)			(302	)			68
Accumulated deficit			(1,036,145	)			(961,747	)
Total stockholders' equity			68,599				122,886
Total liabilities and stockholders' equity		$	314,534			$	313,801

Outset Medical, Inc. Condensed Statements of Cash Flows (in thousands) (unaudited)
		Six Months Ended June 30,
		2024				2023
Net cash used in operating activities		$	(79,247	)		$	(72,932	)
Net cash (used in) provided by investing activities			(20,090	)			29,796
Net cash provided by financing activities			68,687				6,320
Net decrease in cash, cash equivalents and restricted cash			(30,650	)			(36,816	)
Cash, cash equivalents and restricted cash at beginning of the period			71,838				76,533
Cash, cash equivalents and restricted cash at end of the period (1)		$	41,188			$	39,717
(1) The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed balance sheets that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands):
		June 30,
		2024				2023
Cash and cash equivalents		$	37,859			$	36,388
Restricted cash			3,329				3,329
Total cash, cash equivalents and restricted cash*		$	41,188			$	39,717
* The total cash, including restricted cash, cash equivalents and investment securities as of June 30, 2024 was $198.2 million; compared to $226.1 million as of June 30, 2023.

Appendix A
Outset Medical, Inc. Results of Operations – Non-GAAP (in thousands, except per share amounts) (unaudited)
Reconciliation between GAAP and non-GAAP net loss per share:
		Three Months Ended										Six Months Ended
		June 30,										June 30,
		2024					2023					2024					2023
GAAP net loss per share, diluted		$	(0.66	)			$	(0.90	)			$	(1.45	)			$	(1.79	)
Stock-based compensation expense			0.19					0.21					0.35					0.38
Severance and related charges, net			—					—					0.05					—
Non-GAAP net loss per share, diluted		$	(0.47	)			$	(0.69	)			$	(1.05	)			$	(1.41	)
Reconciliation between GAAP and non-GAAP net loss:
		Three Months Ended										Six Months Ended
		June 30,										June 30,
		2024					2023					2024					2023
GAAP net loss, diluted		$	(34,454	)			$	(44,046	)			$	(74,398	)			$	(89,384	)
Stock-based compensation expense			9,820					10,105					18,023					18,643
Severance and related charges, net			(49	)				—					2,426					—
Non-GAAP net loss, diluted		$	(24,683	)			$	(33,941	)			$	(53,949	)			$	(70,741	)
Reconciliation between GAAP and non-GAAP results of operations:
		Three Months Ended										Six Months Ended
		June 30,										June 30,
		2024					2023					2024					2023
GAAP gross profit		$	9,782				$	7,703				$	17,997				$	14,131
Stock-based compensation expense			531					403					796					761
Severance and related charges, net			(78	)				—					201					—
Non-GAAP gross profit		$	10,235				$	8,106				$	18,994				$	14,892
GAAP gross margin			35.7		%			21.4		%			32.4		%			20.3		%
Stock-based compensation expense			1.9					1.1					1.4					1.1
Severance and related charges, net			(0.3	)				—					0.4					—
Non-GAAP gross margin			37.3		%			22.5		%			34.2		%			21.4		%
GAAP research and development expense		$	9,734				$	14,906				$	22,369				$	28,699
Stock-based compensation expense			(2,293	)				(2,824	)				(4,625	)				(5,439	)
Severance and related charges, net			29					—					(963	)				—
Non-GAAP research and development expense		$	7,470				$	12,082				$	16,781				$	23,260
GAAP sales and marketing expense		$	18,128				$	24,985				$	39,176				$	49,318
Stock-based compensation expense			(2,494	)				(3,545	)				(3,953	)				(6,143	)
Severance and related charges, net			(99	)				—					(892	)				—
Non-GAAP sales and marketing expense		$	15,535				$	21,440				$	34,331				$	43,175
GAAP general and administrative expense		$	12,684				$	11,290				$	24,128				$	23,077
Stock-based compensation expense			(4,502	)				(3,333	)				(8,649	)				(6,300	)
Severance and related charges, net			41					—					(370	)				—
Non-GAAP general and administrative expense		$	8,223				$	7,957				$	15,109				$	16,777
GAAP total operating expense		$	40,546				$	51,181				$	85,673				$	101,094
Stock-based compensation expense			(9,289	)				(9,702	)				(17,227	)				(17,882	)
Severance and related charges, net			(29	)				—					(2,225	)				—
Non-GAAP total operating expense		$	31,228				$	41,479				$	66,221				$	83,212

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240807985057/en/

Investor Contact

Jim Mazzola

Investor Relations

jmazzola@outsetmedical.com

Source: Outset Medical, Inc.

FAQ

What was Outset Medical's revenue for Q2 2024?

Outset Medical (OM) reported revenue of $27.4 million for Q2 2024, compared to $36.0 million in Q2 2023.

How did Outset Medical's gross margin change in Q2 2024?

Outset Medical's total gross margin improved to 35.7% in Q2 2024, up from 21.4% in Q2 2023.

What is Outset Medical's revised revenue guidance for 2024?

Outset Medical (OM) revised its 2024 revenue guidance to approximately $110 million, down from the previous range of $145-$153 million.

How did Outset Medical's recurring revenue perform in Q2 2024?

Outset Medical's recurring revenue from Tablo cartridges and service increased by 24% compared to the same period in 2023.